Home LiteratureArticle Details
PMID: 15788737 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Leukocyte-platelet aggregates in rat peripheral blood after ischemic stroke and reperfusion.

Biological research for nursing ·Vol. 6 ·No. 4 ·2005-04-00 ·Pages 281-8

Ritter LS, Stempel KM, Coull BM, McDonagh PF

Abstract

Ischemic stroke and reperfusion (ISR) is associated with an inflammatory response characterized, in part, by the formation of leukocyte-platelet aggregates (LPA). Aggregate formation may amplify the immunologic and hemostatic functions of both cell types and thus exacerbate reperfusion injury after ischemic stroke. LPA formation in peripheral blood may also serve as a biomarker of the severity of injury. However, it is not fully known whether ISR causes LPA formation that can be detected in the peripheral blood. Therefore, the purpose of this study was to measure LPA in the peripheral blood after ISR using a rat model. The filament method was used to perform ISR. Blood was collected from the jugular vein before ischemia, after 4 hours of ischemia, and after 1 hour of reperfusion. Flow cytometry was used to quantify LPA in peripheral blood. Separate ISR groups were treated with tirofiban, a platelet GPIIb/IIIa inhibitor, and fucoidan, a selectin adhesion molecule inhibitor, and analyzed for LPA. Leukocyte CD11b expression and reactive oxygen species production were also analyzed to note the role of polymorphonuclear neutrophilic (PMN) activation on LPA formation. After ISR, LPA levels in peripheral blood were twice as large as preischemic levels. Both GPIIb/IIIa and selectin adhesion molecule inhibition (p < .05) decreased LPA to preischemic values. PMN CD11b expression was increased above baseline but did not differ between groups. Reactive oxygen species production did not differ between groups during reperfusion. These data suggest that ischemic stroke and reperfusion results in an increase in LPA that can be consistently measured in peripheral blood. LPA formation may be a useful biomarker and potential therapeutic target after ischemic stroke and reperfusion.

MeSH Terms
Analysis of Variance Animals Anticoagulants/therapeutic use Biomarkers/blood Blood Platelets/immunology Brain Ischemia/complications Disease Models, Animal Flow Cytometry Inflammation Leukocytes/immunology Male Myocardial Reperfusion Injury/blood,etiology,immunology,prevention & control Neutrophil Activation Neutrophils/immunology Platelet Aggregation/immunology Platelet Aggregation Inhibitors/therapeutic use Polysaccharides/therapeutic use Rats Rats, Sprague-Dawley Reactive Oxygen Species/immunology Severity of Illness Index Stroke/complications Time Factors Tirofiban Tyrosine/analogs & derivatives,therapeutic use
Chemicals
Anticoagulants Biomarkers Platelet Aggregation Inhibitors Polysaccharides Reactive Oxygen Species Tyrosine fucoidan Tirofiban
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Ritter Leslie S
University of Arizona, College of Nursing, Department of Neurology, Sarver Heart Center, PO Box 245023, Tucson, AZ 85724-5023, USA. lritter@nursing.arizona.edu
Stempel Karl M
Coull Bruce M
McDonagh Paul F
Article Info
Journal
Biological research for nursing
Abbr.
Biol Res Nurs
ISSN
1099-8004
Published
2005-04-00
Pages
281-8
Language
English
Region
United States
NLM ID
9815758
Subset
IM
Grants
NHLBI NIH HHS · HLB 58859 · United States
NINR NIH HHS · NR 05208 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com